Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Maze Therapeutics, Inc.NASDAQ: MAZE
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 38.7% from a year ago
Other current assets stood at $7.4M at the end of Q1 FY2026, up 38.7% from a year earlier and down 5.2% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.
Context
- Other current assets amounted to 1.8% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Other current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +38.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 7.8M USD
- Year-over-year change
- +60.5%
- 3-year CAGR
- +7.8%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.8M | +60.5% |
| FY2024 | 2024-12-31 | 4.86M | -1.9% |
| FY2023 | 2023-12-31 | 4.95M | -20.5% |
| FY2022 | 2022-12-31 | 6.23M | — |
Other Current Assets vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +38.7% is the 7th highest of 8, against a peer median of +60.9%.
- Other current assets amounts to 1.8% of total assets for MAZE, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €131.5M EUR | +37579.7% | +141.4% | 52.8% | |
| Jun 2026 | $57.88M USD | +8.1% | -14.0% | 1.8% | |
| Sep 2026 | $43.58M USD | +55.4% | +24.2% | 5.1% | |
| Mar 2026 | $23.58M USD | +60.9% | +38.4% | 4.7% | |
SEPNSepterna, Inc. | Sep 2026 | $9.86M USD | +2448.8% | +78.1% | 1.6% |
BIOABioAge Labs, Inc. | Mar 2026 | $7.96M USD | +102.3% | +133.7% | 2.0% |
| Mar 2026 | $7.4M USD | +38.7% | +7.8% | 1.8% | |
| Mar 2026 | $1.03M USD | +59.0% | — | 1.9% | |
| Peer median (excluding MAZE) | — | +60.9% | +58.3% | 2.0% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.